KM Research Hub

LITERATURE

符合新入排标准的活动候选

仅显示 v3 复核后仍在自动处理队列中的候选论文。 共 1883 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.Gastric CancerPMID 34363528PMC85021402021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).Future OncolPMID 34423676无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).Eur J CancerPMID 34464782无 PMCID2021-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).Eur J CancerPMID 34507244无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).Gynecol OncolPMID 34521554无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.Oral OncolPMID 34560383无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.Eur J CancerPMID 34563992无 PMCID2021-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.Eur J CancerPMID 34597975无 PMCID2021-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.Lancet OncolPMID 34600602PMC93774122021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.Lancet OncolPMID 34655533无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet OncolPMID 34656227PMC85606422021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.Nat MedPMID 34737452无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.JCO Precis OncolPMID 34994614无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.BloodPMID 34157093PMC97104692021-Oct-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.Clin Cancer ResPMID 34326132PMC94014932021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.Signal Transduct Target TherPMID 34650034PMC85170122021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).BMC CancerPMID 34654402PMC85182652021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.J Clin OncolPMID 34379443PMC85006032021-Oct-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.J Clin OncolPMID 34048275PMC84783922021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Clin Cancer ResPMID 34158360PMC94014852021-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.Clin Cancer ResPMID 34301751PMC96629112021-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.J Clin OncolPMID 34343033PMC84784032021-Oct-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.JAMA OncolPMID 34351356PMC83435042021-Oct-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.J Clin OncolPMID 34357781PMC84783862021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.JAMA OncolPMID 34383006PMC85319922021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Blood Cancer JPMID 34599139PMC84868172021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.Ann Surg OncolPMID 33641012PMC79140392021-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
The HELENA study: Hexvix®-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study.World J UrolPMID 34002265PMC85215132021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases.SurgeryPMID 34030885无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.J UrolPMID 34039013无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.Clin Lymphoma Myeloma LeukPMID 34059488PMC85281792021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).OncologistPMID 34105207PMC84888002021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.LeukemiaPMID 34274940PMC87440702021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.Expert Rev Anticancer TherPMID 34281470无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.Gynecol OncolPMID 34353615PMC95551192021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.Ann OncolPMID 34384882无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.Cancer Immunol ResPMID 34389558PMC94142802021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.Lung CancerPMID 34403911无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.Eur J CancerPMID 34418665无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).Eur J CancerPMID 34450552无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.Br J CancerPMID 34480096PMC85485172021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.Lung CancerPMID 34482102无 PMCID2021-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.Lancet OncolPMID 34529931无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.Cancer MedPMID 34549539PMC85251252021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.Breast Cancer Res TreatPMID 34553296PMC85053152021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.ESMO OpenPMID 34607285PMC84935932021-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).Int J Gynecol CancerPMID 34607820无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J MedPMID 34551229无 PMCID2021-Sep-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.J Clin OncolPMID 34185551PMC84455622021-Sep-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J MedPMID 34161051PMC84463322021-Sep-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理